Abstract: Objective To discuss the safety and effectiveness of transurethral plasmakinetic lobes-enucleation of prostate for patients with benign prostatic hyperplasia. Methods Totally 27 patients who underwent transurethral plasmakinetic lobes-enucleation of prostate from September 2017 to May 2018 by the same surgeon in our institution were included in this study. Patients were assessed at one month postoperatively to evaluate the safety and effectiveness of this operation. Results All operation was performed successfully. The mean age of patients was(63.7±7.3) years, with mean preoperative prostate weight of(64.5±23.9) g,mean operating time of(64.3±35.4) min and mean resected tissue weight of(44.5±20.8) g. The decrease in hemoglobin after surgery was(1.28±1.12) g/dl, and the mean catheter dwelling time was(66.1±12.4) hours and hospitalization time was(7.4±2.8) days. Patients were assessed at one month postoperatively, and the prostate specific antigen(PSA) level (3.5±1.6) ng/ml vs(1.0±0.7) ng/ml, HR=0.009 and transrectal ultrasound(TRUS) weight (64.5±23.9) g vs(21.8±7.7) g, HR=0.001 reduced significantly. And there was a significant improvement in maximum urinary flow rate(Qmax) (17.6±8.4) ml/s vs(5.1±3.1) ml/s,HR=0.004. Both international prostate symptom score(IPSS) and quality of life(QoL) scores improved significantly IPSS,(17.5±4.5) vs(8.7±4.5); QoL,(4.6±0.4) vs(1.3±0.5); P<0.001, respectively. No patient experienced incontinence, clot retention, urethral stricture and bladder neck contracture. Two patients(7.4%) had urinary tract infection, and one patient(3.7%)experienced urinary retention after discharged because of detrusor under activity. Conclusion Transurethral plasmakinetic lobesenucleation of prostate is a safe and effective method in treatment of benign prostatic hyperplasia.